HighVista Strategies’s Cardiff Oncology CRDF Stock Holding History

HighVista Strategies’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15,501	Closed	-$103K	–	78
2021 Q3	$103K	Buy	+15,501	New	+$97.4K	0.07%	96

Other funds holding CRDF

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighVista Strategies's CRDF Position: Q4 2021 in Review

HighVista Strategies sold out of Cardiff Oncology (CRDF) in Q4 2021, closing a stake of 15,501 shares — an estimated $103K sold.

HighVista Strategies first reported a position in CRDF in Q3 2021 and held it in 1 quarter. The position peaked at $103K in Q3 2021. 87 funds tracked by Wall St. Rank hold CRDF as of Q4 2021.

HighVista Strategies reported no remaining Cardiff Oncology position as of Q4 2021 after selling out during the quarter.
HighVista Strategies sold 15,501 Cardiff Oncology shares in Q4 2021, an estimated $103K.
HighVista Strategies first reported a position in Cardiff Oncology in Q3 2021 and held it in 1 quarter.
HighVista Strategies's Cardiff Oncology position peaked at $103K in Q3 2021.
87 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.